Search Medical Condition
Please enter condition
Please choose location from dropdown

Port St. Lucie, Florida Clinical Trials

A listing of Port St. Lucie, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (44) clinical trials

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults

The Trial comprises 2 Parts, Part A and Part B. Part A is a randomized, open-label, multi-center, comparative design to assess the efficacy and safety in subjects with ACV-resistant mucocutaneous HSV infection, treated with oral pritelivir or intravenous foscarnet. Part B is an open-label, multi-center design to assess the efficacy ...

Phase

8.39 miles

Learn More »

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive HIV-1 and Hepatitis B Co-Infected Adults

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV and hepatitis B virus (HBV) treatment naive, HIV-1 and HBV co-infected adults.

Phase

8.39 miles

Learn More »

Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed HIV-1 Infected African American Participants

The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing their baseline regimen in HIV-1 infected, virologically suppressed African American participants.

Phase

8.39 miles

Learn More »

Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Part 1: Approximately 66 subjects will be randomized in a 1:1:1 ratio to the following dose groups Zimura Dose Administration 1 Zimura Dose Administration 2 Sham Administration 1 Part 2: Approximately 135 subjects will be randomized in a 1:2:2 ratio to the following dose groups Zimura Dose Administration 3 Zimura ...

Phase

8.76 miles

Learn More »